Analyst Price Target is $12.86
▲ +167.86% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $12.86, with a high forecast of $26.00 and a low forecast of $5.00. The average price target represents a 167.86% upside from the last price of $4.80.
Current Consensus is
Moderate Buy
The current consensus among 10 polled investment analysts is to moderate buy stock in 2seventy bio. This Moderate Buy consensus rating has held steady for over two years.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More